Virtus Biotech Etf (BBP)
$102,50
▼ -0,71 (-0,69%)
1-Tages-Veränderung
$100,91 – $110,05
52-Wochen-Spanne
Gewichtung der Top-10-Positionen19,61%
Effektive Anzahl von Positionen64,2
Positionen über 1%65
Nettovermögen
$98.5M
Bestände
70
Stand
31. Juli 2026
BBP Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Performance Stand 2. Oktober 2026
| Zeitraum | Preisrendite | Gesamtrendite |
|---|---|---|
| 1M | ▼ -6,53% | ▼ -6,53% |
| 3M | · | · |
| 6M | · | · |
| YTD | · | · |
| 1Y | · | · |
| 3Y | · | · |
| 5Y | · | · |
| Max | ▼ -0,95% | ▼ -0,95% |
Volatilität 1J·
Volatilität 3J·
Max. Drawdown 3J
·
Beta 3J·
Sharpe 1J*·
Gesamtrendite unterstellt die Reinvestition von Dividenden. Renditen werden nicht gegen einen Index abgeglichen. * Die Sharpe Ratio wird mit einem risikofreien Zinssatz von 0% berechnet.
Fondsflüsse (SEC-gemeldet)
Letzter Monat (Jul 2026)
+$14.9M
Quartalsende Jul 2026
+$32.2M
Letzte 12 Monate
+$56.3M
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Vollständige Zusammensetzung 70 Beteiligungen
| Name | CUSIP | Wert | % | Bilanz | Kategorie | Land |
|---|---|---|---|---|---|---|
| CRINETICS PHARMACEUTICALS INC | 22663K107 | $3.3M | 3,34 | 39.373 | EC | US |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | · | $1.9M | 1,97 | 26.155 | EC | GB |
| VERASTEM INC | 92337C203 | $1.9M | 1,95 | 331.013 | EC | US |
| PRECIGEN INC | 74017N105 | $1.9M | 1,94 | 304.977 | EC | US |
| OMEROS CORP | 682143102 | $1.8M | 1,87 | 155.369 | EC | US |
| NUVATION BIO INC | 67080N101 | $1.7M | 1,77 | 275.843 | EC | US |
| REGENERON PHARMACEUTICALS | 75886F107 | $1.7M | 1,72 | 2.218 | EC | US |
| PROTAGONIST THERAPEUTICS INC | 74366E102 | $1.7M | 1,71 | 12.363 | EC | US |
| ACADIA PHARMACEUTICALS INC | 004225108 | $1.7M | 1,69 | 64.350 | EC | US |
| BRIDGEBIO PHARMA INC | 10806X102 | $1.6M | 1,65 | 20.315 | EC | US |
| BEONE MEDICINES LTD | 07725L102 | $1.6M | 1,65 | 5.132 | EC | CH |
| XERIS BIOPHARMA HOLDINGS INC | 98422E103 | $1.6M | 1,64 | 199.875 | EC | US |
| HALOZYME THERAPEUTICS INC | 40637H109 | $1.6M | 1,64 | 19.528 | EC | US |
| LIQUIDIA CORP | 53635D202 | $1.6M | 1,63 | 19.053 | EC | US |
| IMMUNOCORE HOLDINGS PLC | 45258D105 | $1.6M | 1,61 | 46.863 | EC | GB |
| IRONWOOD PHARMACEUTICALS INC | 46333X108 | $1.6M | 1,60 | 371.823 | EC | US |
| ARROWHEAD PHARMACEUTICALS INC | 04280A100 | $1.5M | 1,56 | 18.212 | EC | US |
| ROIVANT SCIENCES LTD | · | $1.5M | 1,55 | 45.179 | EC | BM |
| LIGAND PHARMACEUTICALS | 53220K504 | $1.5M | 1,55 | 5.310 | EC | US |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | $1.5M | 1,55 | 15.357 | EC | US |
| GERON CORP | 374163103 | $1.5M | 1,54 | 1.180.129 | EC | US |
| RIGEL PHARMACEUTICALS INC | 766559702 | $1.5M | 1,54 | 41.313 | EC | US |
| ASCENDIS PHARMA A/S | · | $1.5M | 1,54 | 6.224 | EC | DK |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | $1.5M | 1,52 | 55.666 | EC | US |
| INCYTE CORP | 45337C102 | $1.5M | 1,52 | 12.506 | EC | US |
| CYTOKINETICS INC | 23282W605 | $1.5M | 1,51 | 19.346 | EC | US |
| MODERNA INC | 60770K107 | $1.5M | 1,51 | 27.191 | EC | US |
| AMGEN INC | 031162100 | $1.5M | 1,49 | 3.820 | EC | US |
| TRAVERE THERAPEUTICS INC | 89422G107 | $1.5M | 1,48 | 26.078 | EC | US |
| KRYSTAL BIOTECH INC | 501147102 | $1.5M | 1,48 | 4.269 | EC | US |
| VERTEX PHARMACEUTICALS INC | 92532F100 | $1.5M | 1,48 | 3.052 | EC | US |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | $1.5M | 1,48 | 24.255 | EC | US |
| ZAI LAB LTD | 98887Q104 | $1.5M | 1,47 | 79.505 | EC | KY |
| MIRUM PHARMACEUTICALS INC | 604749101 | $1.4M | 1,47 | 13.661 | EC | US |
| DENALI THERAPEUTICS INC | 24823R105 | $1.4M | 1,46 | 62.658 | EC | US |
| TG THERAPEUTICS INC | 88322Q108 | $1.4M | 1,45 | 27.407 | EC | US |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | $1.4M | 1,44 | 8.494 | EC | US |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | $1.4M | 1,44 | 74.364 | EC | US |
| GILEAD SCIENCES INC | 375558103 | $1.4M | 1,43 | 10.807 | EC | US |
| BIOCRYST PHARMACEUTICALS INC | 09058V103 | $1.4M | 1,42 | 155.993 | EC | US |
| ADMA BIOLOGICS INC | 000899104 | $1.4M | 1,42 | 165.305 | EC | US |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | $1.4M | 1,41 | 55.734 | EC | US |
| HARMONY BIOSCIENCES HOLDINGS INC | 413197104 | $1.4M | 1,41 | 39.383 | EC | US |
| AGIOS PHARMACEUTICALS INC | 00847X104 | $1.4M | 1,40 | 46.067 | EC | US |
| BIOGEN INC | 09062X103 | $1.4M | 1,40 | 6.785 | EC | US |
| THERAVANCE BIOPHARMA INC | · | $1.4M | 1,40 | 81.560 | EC | KY |
| IMMUNITYBIO INC | 45256X103 | $1.4M | 1,39 | 191.148 | EC | US |
| INSMED INC | 457669307 | $1.4M | 1,39 | 13.870 | EC | US |
| BIONTECH SE | 09075V102 | $1.4M | 1,38 | 14.989 | EC | DE |
| EXELIXIS INC | 30161Q104 | $1.4M | 1,37 | 25.544 | EC | US |
Sektoraufschlüsselung
Dividenden 2 Zahlungen
0,00%Rendite (TTM)
$0,00Ausschüttung (TTM) / Aktie
Unregelmäßig
(gesch.)
| Ex-Datum | Betrag / Aktie |
|---|---|
| 20. Dezember 2017 | $0,0720 |
| 21. Dezember 2015 | $0,3970 |
Institutionelle Eigentümer (13F) 27 Einreicher
Institutionen, die diese ETF in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann zweimal für separate Optionskontrakte erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Institution | Wert | % der verfolgten 13F | Aktien | Typ | Stand |
|---|---|---|---|---|---|
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $10.464.537 | 27,96% | 104.374 | Aktien | 30. Juni 2026 |
| ROYAL BANK OF CANADA | $9.354.000 | 24,99% | 97.170 | Aktien | 30. Juni 2026 |
| RAYMOND JAMES FINANCIAL INC | $1.983.710 | 5,30% | 20.606 | Aktien | 30. Juni 2026 |
| CWA Asset Management Group, LLC | $1.791.174 | 4,79% | 18.606 | Aktien | 30. Juni 2026 |
| ENVESTNET ASSET MANAGEMENT INC | $1.755.458 | 4,69% | 18.235 | Aktien | 30. Juni 2026 |
| Cetera Investment Advisers | $1.702.510 | 4,55% | 17.685 | Aktien | 30. Juni 2026 |
| TWO SIGMA INVESTMENTS, LP | $1.636.566 | 4,37% | 17.000 | Aktien | 30. Juni 2026 |
| WBI INVESTMENTS, LLC | $1.613.080 | 4,31% | 16.756 | Aktien | 30. Juni 2026 |
| LPL Financial LLC | $1.243.501 | 3,32% | 12.917 | Aktien | 30. Juni 2026 |
| Prime Capital Investment Advisors, LLC | $1.146.945 | 3,06% | 11.914 | Aktien | 30. Juni 2026 |
| MORGAN STANLEY | $1.094.574 | 2,92% | 11.370 | Aktien | 30. Juni 2026 |
| Advisor Resource Council | $1.068.550 | 2,85% | 10.761 | Aktien | 30. Juni 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.037.487 | 2,77% | 10.777 | Aktien | 30. Juni 2026 |
| INDEPENDENT FINANCIAL GROUP, LLC | $719.704 | 1,92% | 7.476 | Aktien | 30. Juni 2026 |
| Kestra Advisory Services, LLC | $400.472 | 1,07% | 4.160 | Aktien | 30. Juni 2026 |
| FOUNDERS FINANCIAL SECURITIES LLC | $216.316 | 0,58% | 2.247 | Aktien | 30. Juni 2026 |
| CWM, LLC | $59.556 | 0,16% | 717 | Aktien | 31. März 2026 |
| Institute for Wealth Management, LLC. | $34.272 | 0,09% | 356 | Aktien | 30. Juni 2026 |
| OSAIC HOLDINGS, INC. | $30.124 | 0,08% | 313 | Aktien | 30. Juni 2026 |
| COMERICA BANK | $17.342 | 0,05% | 217 | Aktien | 31. Dezember 2025 |
| FIFTH THIRD BANCORP | $14.537 | 0,04% | 151 | Aktien | 30. Juni 2026 |
| Byrne Asset Management LLC | $13.670 | 0,04% | 142 | Aktien | 30. Juni 2026 |
| Steward Partners Investment Advisory, LLC | $11.071 | 0,03% | 115 | Aktien | 30. Juni 2026 |
| Allworth Financial LP | $6.836 | 0,02% | 71 | Aktien | 30. Juni 2026 |
| Glen Eagle Advisors, LLC | $4.813 | 0,01% | 50 | Aktien | 30. Juni 2026 |
| Thrivent Financial for Lutherans | $4.322 | 0,01% | 44.897 | Aktien | 30. Juni 2026 |
| Farther Finance Advisors, LLC | $2.214 | 0,01% | 23 | Aktien | 30. Juni 2026 |